Background: Cerebrospinal fluid (CSF) levels assessment of Aβ and Tau proteins may be accurate diagnostic biomarkers for the differentiation of preclinical Alzheimer's disease (AD) from age-associated memory impairment, depression and other forms of dementia in patients with mild cognitive impairment (MCI). The aim of our study was to explore the utility of CSF biomarkers in combination with common cognitive markers as predictors for the risk of AD development, and other forms of dementia, and the time to conversion in community patients with MCI. Methods: A group of 71 MCI patients underwent neurological assessment, extended neuropsychological evaluation, routine blood tests, ApoE determination, and lumbar puncture to dose t-tau, p-tau 181 , Aβ 1-42 . We investigated baseline CSF and neuropsychological biomarker patterns according to groups stratified with later diagnoses of AD conversion (MCI-AD), other dementia (MCI-NAD) conversion, or clinical stability (sMCI). Results: Baseline Aβ 1-42 CSF levels were significantly lower in MCI-AD patients compared to both sMCI and MCI-NAD. Additionally, p-tau 181 was higher in the MCI-AD group compared to sMCI. The MCI-AD subgroup analysis confirmed the role of Aβ 1-42 in its predictive role of time to conversion: rapid converters had lower Aβ 1-42 levels compared to
Introduction
Alzheimer's disease (AD) is a chronically progressive neurodegenerative disease and the most common form of dementia in the elderly. It is well known that AD pathological processes appear gradually and begin to develop decades before the onset of clinical symptoms, with dementia representing the end stage of many years of accumulation of these pathological changes [1] . In this continuum, mild cognitive impairment (MCI) has been considered as a half way condition between normal cognition and dementia, with an annual rate of progression to AD of 15% [2] .
However, not all patients exhibiting MCI will develop AD. Therefore, the possibility of identifying individuals carrying incipient AD in the MCI population has become of utmost importance. Expert consensus groups have recommended possible primary biomarker candidates, including cerebrospinal fluid (CSF) level of amyloid-β 1-42 (Aβ ), total-tau (t-tau), and phosphorylated tau (p-tau), as well as MRI-based assessments of the hippocampus and enthorinal cortex and neuropsychological markers of memory and non-memory cognitive ability [3] .
There are multiple advantages associated with identifying predictive prognostic indicators of conversion from MCI to AD, including the empowerment for patients and their families to prepare for the future, and the appropriate allocation of early treatment with disease modifying drugs in clinical trials to patients with biomarker indications of early conversion to AD whilst not exposing patients unlikely of AD conversion to undue risk. Further, the biomarkers may also be advantageous in prognosis, disease progression analysis, treatment development, treatment effect monitoring and the study of disease mechanism.
CSF biomarkers represent a direct measure of cerebral pathological changes occurring in the AD process. Neurofibrillary tangles and amyloid plaques are the principal pathologic features of AD and it has been suggested that abnormal processing of amyloid precursor protein leads to a cascade of events characterized by abnormal tau aggregations, synaptic dysfunction, cell death, and changes in brain structure [4] . Aβ 1-42 is a peptide produced from the cleavage of the amyloid precursor protein (APP) from α and γ secretase enzymes. Among different types of Aβ peptides, Aβ has been shown to have the higher specificity and sensitivity in detecting incipient AD. Aβ in CSF has been proven to be significantly reduced in subjects with AD compared to age-matched controls, by about 50% [5] . Tau proteins are also altered; tau becomes hyperphosphylated and dissociates from the microtubules in AD, causing an increase of CSF total and p-tau [6] in AD subjects.
Several studies have shown that the relative risk of progression from MCI to AD is increased in patients with high baseline tau and p-tau, and low Aβ with high sensitivity and specificity [7] [8] [9] [10] [11] [12] [13] [14] [15] . Following progress in research, a working group established by the National Institute of Aging in 2011 promoted a revision of the diagnostic criteria for AD and MCI, recommending the adoption of CSF biomarkers for the identification of patients with 'MCI due to AD' in research setting, i.e., patients at high risk to develop AD [16] .
The potential of these biomarkers under standardized settings has proven to be effective, with a high diagnostic performance in a homogeneous mono-center population [17] . However, standardization of these biomarkers is currently limited and laboratory results often vary [18, 19] . Community studies are therefore required in order to validate the diagnostic accuracy of CSF measures in everyday clinical settings.
In this study, we explored the utility of CSF biomarkers in combination with standard cognitive markers to identify MCI patients at risk of conversion to AD and other forms of dementia, in a clinical setting over a 2-year period. We evaluated the best parameter (or combinations of them) for predicting conversion to dementia and time to conversion in a general clinical population, transferring the research approach with precise patient selection used in large cohort studies into a real world clinical scenario. , t-tau and p-tau were measured. Subjects were subsequently followed up clinically every 6 months for at least of 24 months (range 24-31 months) and classified according to whether they had developed AD (MCI-AD converters) or other dementias (MCI-NAD) or whether they had remained stable (sMCI). Baseline differences in CSF and neuropsychological biomarkers patterns were investigated, and MCI patients were stratified according to eventual diagnoses of conversion to AD or other dementia.
Materials and methods

Patients
Among the patient cohort, 23 remained stable (sMCI), 31 developed AD (MCI-AD), and 17 developed non-AD dementia (i.e., frontotemporal dementia, vascular dementia, etc.). In addition, according to literature data suggesting that MCI-AD conversion appears to be time dependent, and occurs primarily within the initial 18 months [20] , we further classified MCI-AD patients as rapid (n = 16, ≤ 18 months) or slow (n = 15, > 18 months) converters. Clinical diagnoses of amnestic MCI, probable AD or other dementias were made according to published criteria [21] [22] [23] [24] [25] .
CSF sampling
Lumbar punctures were performed in the morning in fasting patients; all subjects gave written consent to undergo the lumbar puncture. Approximately 7 mL CSF were collected in sterile polypropylene tubes and transported to the adjacent laboratory within 30 min. CSF was centrifuged for 15 min at 2700 g at controlled room temperature and aliquoted in polypropylene storage tubes. To reduce the possibility of surface adsorption, we aliquoted 400 μL CSF in 500 μL tubes. If not immediately analyzed, storage tubes were frozen at -80 °C awaiting testing. CSF Aβ 1-42 , t-tau, and p-tau 181 were measured with the ELISA method following manufacturer instructions (Innogenetics, Gent, Belgium). All tests were performed in the same laboratory by the same biologist in accordance with recent guidelines [26] . The inter-assay coefficients of variation (CVs) were within 8.6% for t-tau, 14.1% for Aβ 1-42 , 10.9% for p-tau 181 .
Analysis of demographical, neuropsychological, and CSF data
Baseline demographic, neuropsychological, and CSF data were analyzed with SPSS 20.0 and STATA11 software using parametric or non-parametric tests, as appropriate. First, we investigated baseline Table 1 Baseline demographic, cognitive and CSF characteristics of MCI samples. Binary logistic regression analyses were performed to distinguish MCI-AD from sMCI and MCI-AD from MCI-NAD. The accuracy of these models were assessed by area under the curve (AUC) of the receiver operating characteristic (ROC) curve. A multinomial logistic regression analysis was then performed to explore the prediction accuracy among the three groups of patients considered together in the analysis. A survival analysis (Cox regression model) was performed to obtain significant predictors of conversion to AD and of time of conversion. Kaplan-Meier survival analysis was used to determine median dementia-free survival time. Finally, the MCI-AD subgroup was further analyzed according to rapid and slow conversion and an independent t-test was used to compare the CSF biomarkers in the two groups.
Baseline characteristics MCI-AD
(n = 31) MCI-NAD (n = 17) sMCI (n = 23) Gender, F/M 17/14 9/8 13/10 Age, years, mean (SD) 66.2 ( ± 9.4) 66.4 ( ± 7.6) 68.1 ( ± 8.3) Education, years, mean (SD) 10.4 ( ± 5.7) 9.5 ( ± 4.5) 8.8 ( ± 6.4) ApoE4 carrier, y/n 10/21 4/13 2/21 MMSE, mean (SD) 25.1 ( ± 3.1) 25.4 ( ± 2.2) 26.8 ( ± 2.3) Semantic fluency, mean (SD) 31 ( ± 1.9) 35 ( ± 1.7) 38 ( ± 3.6) Phonemic fluency, mean (SD) c 21 ( ± 11.1) 19 ( ± 13.1) 29 ( ± 9.3) Babcock story recall, mean (SD) 5.04 ( ± 1.2) 7.9 ( ± 5.2) 6.5 ( ± 5.7) Rey-Osterrieth Figure-delay recall, mean (SD) b 6.1 ( ± 7.1) 6.9 ( ± 5.2) 11.4 ( ± 5.3) Frontal Assessment
Results
At baseline, there were no significant differences between the groups in terms of age, years of education, gender, MMSE, semantic fluency, prose memory, and t-tau. ApoE4 genotype was prevalent in MCI-AD group compared to other groups, but the difference did not reach statistical significance after correction for multiple comparisons. Figure 1 ). The subgroup analysis performed in the three subgroups of MCI patients separately (MCI-AD, sMCI, MCI-NAD) revealed that only in MCI-AD group there was a significant positive correlation between the three measures; no statistically significant correlation was found in sMCI and MCI-NAD. Other cognitive measures, Aβ 1-42 or other CSF peptides were not correlated.
Logistic regression analyses showed that Aβ 1-42 was helpful in differentiating MCI converters from sMCI and both Aβ 1-42 and p-tau were helpful in discriminating between MCI-AD and MCI-NAD. The logistic regression considering MCI-AD versus sMCI as diagnostic status and MMSE, ApoE status, t-tau, p-tau and Aβ 1-42 as independent variables showed that only Aβ 1-42 was helpful in differentiating MCI converters from sMCI (β = -0.014, SE = 0.006, p = 0.034). This model accounted for between 53% and 72% of the variance in conversion status, with an overall prediction accuracy of 83%. Hosmer and Lemeshow's test indicated a high p-value, confirming the efficiency of the model. Sensitivity and specificity of this model were 95.24% and 80%, respectively (AUC = 0.97 Figure 2B , top), the positive predictive value (PPV) was 95.24% and the negative predictive value (NPV) was 80%.
The logistic regression considering MCI-AD versus MCI-NAD as diagnostic status and the MMSE, ApoE status, t-tau, p-tau and Aβ1-42 as independent variables showed that both Aβ 1-42 (β = -0.007, SE = 0.002, p = 0.014) and p-tau (β = 0.07, SE = 0.032, p = 0.024) were helpful in discriminating between MCI-AD and MCI-NAD (Figure 2A ). This model accounted for between 37% and 52% of the variance in conversion status, with an overall prediction accuracy of 84% for non-converters. Hosmer and Lemeshow's test indicated a high p-value, confirming the efficiency of the model. The sensitivity and specificity of this model were 85.71% and 77.27%, respectively (AUC = 0.87 Figure 2B , bottom), the PPV was 78.26% and the NPV 85%.
The logistic regression considering MCI-AD versus MCI-NAD plus sMCI as diagnostic status (i.e., conversion to AD vs. all other diagnostic status, both stable MCI and MCI converted to other dementia) and MMSE, ApoE status, t-tau, p-tau and Aβ1-42 as independent variables showed that only Aβ 1-42 (β = -0.004, SE = 0.002, p = 0.044) was helpful in discriminating MCI patients destined to convert to AD. This model accounted for between 14% and 19% of the variance in conversion status, with an overall prediction accuracy of 61%. Again efficacy was confirmed with a high p-value indicated from Hosmer and Lemeshow's test. The sensitivity and specificity of this model were 90.91% and 41.18%, respectively (AUC = 0.62), the PPV was 66.67% and the NPV 77.78%. Due to the heterogeneous nature of the groups of subjects in this model, the specificity and the prediction accuracy significantly decreased compared to previous models. The use of Aβ 1-42/ p-tau and Aβ 1-42/ t-tau ratio in these analyses did not improve predictability.
Finally, the multinomial logistic regression considering MCI-AD versus sMCI versus MCI-NAD as diagnostic status and MMSE, ApoE status, t-tau, p-tau and Aβ 1-42 as independent variables showed that Aβ 1-42 was helpful to discriminate between AD-MCI and sMCI (relative risk = 1.01, p = 0.019), whereas all CSF biomarkers were helpful to differentiate AD-MCI from MCI-NAD (relative risk Aβ 1-42 = 1.01, p = 0.023; relative risk t-tau = 1.02, p = 0.031; relative risk p-tau = 0.87, p = 0.035); in this analysis, the MCI-AD group was used as the baseline comparison group. This model accounted for between 61% and 71% of the variance in conversion status, with an overall prediction accuracy of 76.7%, which was greater than the proportional by chance accuracy criteria of 55.6, suggesting that the model was useful.
Survival analysis performed with time to AD conversion as a failure covariate showed that MCI patients with higher value of CSF Aβ 1-42 had a significantly lower risk of AD conversion than individuals with a lower value [hazard ratio (HR) = 0.05; β = -0.006]. The presence of a lower CSF Aβ 1-42 value was associated with a shorter median dementia-free survival (14 months; Figure 3 ). The cut-off value of 500 pg/mL for Aβ 1-42 was adopted to distinguish between low (i.e., pathological) and high (i.e., normal) CSF levels , as suggested by Sjogren et al. [27] . In addition, the subgroup analysis between slow and rapid converters confirmed the role of Aβ in distinguishing between the two groups: rapid converters had lower Aβ 1-42 baseline levels as compared to slow converters (p < 0.05; Figure 4 ). The cut-off value of 500 pg/mL was adopted according to literature data.
Discussion
MCI is a heterogeneous disorder. MCI patients may progress to AD, to other dementing illnesses, (including vascular dementia, fronto-temporal dementia and Lewy body dementia), or remain relatively stable and decline cognitively as in normal aging. Therefore, identifying biomarkers of incipient AD before symptoms of dementia are established has many clinical advantages. Among all biological, cognitive, and neuroimaging markers, it has been demonstrated that the combined pattern of low levels of Aβ 1-42 together with high levels of t-tau and p-tau in CSF may accurately differentiate MCI patients with incipient AD from those with stable MCI [7] .
The aim of the current study was to identify baseline levels of classic CSF biomarkers and assess their powers, either individually or in combination, in predicting conversion to AD or other dementias. Patients were monitored for at least of 24 months. Patients were then classified according to the development of AD (MCI-AD), other dementia (MCI-NAD) and those who remained cognitively stable (sMCI).
Retrospective analysis of baseline levels identified Aβ as an important independent biomarker for differentiating MCI-AD patients, and as an indicator of the time to conversion. A significant reduction of Aβ in MCI-AD compared to both MCI-NAD and sMCI, and a significantly lower level of Aβ in rapid converters (i.e., conversion ≤ 18 months) compared to slow converters (i.e., conversion > 18 months), were found. Additionally, a significant increase of p-tau in MCI-AD compared to sMCI was evidenced, and t-tau levels were lower in the sMCI group compared to MCI-AD and MCI-NAD groups.
Prognostic factors and biomarkers of time of conversion are not well recognized in literature. Some studies showed an association between time of conversion and injury markers, such as CSF p-tau and t-tau [28, 29] , whereas other studies did not find any association [30] or found association with amyloid markers [31] . In our study, Aβ 1-42 CSF value was found to be a predictor not only of conversion, but also of time of conversion, whereas we did not find this association with neurodegeneration markers (i.e., t-tau and p-tau). In a study by Van Rossum and colleagues [28] , the authors found that injury markers but not amyloid markers were associated with faster decline from MCI to AD, but MCI subjects who went on to convert to AD had already at baseline lower MMSE scores compared to subjects who did not progress to AD dementia, suggesting that these patients were already at baseline in a more advanced stage of the disease, where it is well known that markers of neurodegeneration are more useful in predicting prognosis than amyloid markers. On the contrary, in our study, no significant differences between the groups were found in CSF tau level and MMSE at baseline, suggesting that our MCI subjects did not differ in terms of neurodegenerative process stage at the first visit. Maybe, these differences in patient's characteristics and selection criteria may account for the discrepancies emerged in our study compared to previous one in terms of time of conversion. In addition, we cannot rule out the presence of inter-laboratory differences related to the variability of CSF biomarkers assays.
Statistical analyses of different combinations of biomarkers converged to emphasize the central role of Aβ in differentiating the incipient AD type. Aβ 1-42 and p-tau were identified through regression and survival models as the best predictors for discriminating incipient AD in MCI population, in line with previous studies [7, 9, 10, 15, 30, 32] . Additionally, Aβ 1-42 was found to be significantly correlated with memory performances on cognitive tests. This correlation was limited to the MCI-AD group, confirming the early and specific involvement of memory in preclinical phases of the disease [33] . Despite this correlation, common cognitive performances were not found to be strong predictors of AD conversion in our models. These results suggest that CSF biomarkers provide predictive information which cannot be obtained from clinical and neuropsychological assessment only.
Both binary and multinomial logistic regression showed high specificity and sensitivity in detecting AD-MCI among sMCI and MCI-NAD separately, whereas the level of accuracy decreased for the discrimination of incipient AD among more mixed group of patients. As a matter of fact, we cannot exclude the presence of Alzheimer's histopathology in patients clinically classified as sMCI or MIC-NAD, in line with literature data that reported high sensitivity but low specificity for the AD-like CSF profile [34] . Unfortunately, we did not have histopathological examination to support our results. Maybe a longer follow-up could have helped to assess whether patients with sMCI eventually progress to AD-type dementia.
This study is limited by a relative small sample size compared to large research cohort studies. However, the study offers insight into the investigation of the role of biomarkers in a real 'clinical community setting'. The advantages associated with the clinical community setting are mainly associated with patient selection. Large research cohort studies enroll carefully selected MCI participants with extensively documented memory impairment, and often exclude those with impairment arising from other potential causes, resulting in an MCI population which doesn't reflect the general clinical population. The current study is based on a general clinical patient cohort and confirms the utility of biomarkers in detecting AD neuropathological changes in MCI patients. Indeed, we included a heterogeneous group of MCI patients in the testing of specificity and sensitivity of biomarkers in discriminating different neuropathological conditions at a preclinical stage. Additional research is required to validate the application of CSF biomarkers in clinical settings, and procedures for acquisition and analysis of samples need to be established for broad scale application.
Our results suggest that the application of both clinical criteria and CSF biomarkers may reliably predict the conversion of MCI to AD, and the time to conversion, even in a routine diagnostic work-up.
